

Special Issue

Advancements in Lung Cancer Precision Oncology Research and Treatments

Message from the Guest Editors

Lung cancer is one of the most common malignancies and the first cause of cancer death worldwide. Significant improvements in lung cancer survival have been obtained in the last decade by introducing two novel therapeutic approaches for patients affected by non-small cell lung cancer (NSCLC), a histological subtype that includes approximately 85% of lung cancers: immunotherapy and gene-targeted therapy. These treatments are based on identifying predictive biomarkers, revolutionizing daily practice in modern pathology and medical oncology, and bridging consistent survival advantages in NSCLC patients. Currently, EGFR, KRAS, BRAF, ERBB2, ALK, ROS1, MET, RET, and NTRK genetic alterations and PD-L1 immunohistochemical expression are used to make treatment decisions, and a great number of ongoing clinical trials investigate novel molecular targets, medications, treatment combinations and protocols against lung cancer. This Special Issue aims to shed light on the most recent advancements in precision oncology research and current innovations in targeted and immunological treatments against lung cancer.

Guest Editors

Dr. Panagiotis Paliogiannis

Prof. Dr. Giuseppe Palmieri

Dr. Francesca Colonese

Deadline for manuscript submissions

30 September 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/198232

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).